Blog – pTau217 Blood Test for Alzheimer’s: What the FDA Clearance Means
Dr Emma Law on what the FDA clearance of the pTau217 blood test means for dementia research, from recruitment and trial design to where PET imaging still fits.
Dr Emma Law is Strategic Manager for the Neuroprogressive and Dementia Network in Scotland. Emma has 13 years experience as a Clinical Trials Network Manager and over 35 years experience as a Nurse, many of which were spent in the delivery of Clinical Research Trials. Emma completed her PhD and is passionate about giving people living with dementia and their carers access to participate in research.
Dr Emma Law on what the FDA clearance of the pTau217 blood test means for dementia research, from recruitment and trial design to where PET imaging still fits.
Dr Emma Law does her GCP update every two years and wondered why. She traces the rules back to 1947, and shares what changed in her latest refresher
Dr Emma Law explores how researchers manage patient expectations in research while being clear about uncertainty, consent, and the realities of clinical trials.
Emma Law explains how safety is protected in dementia drug trials, from recruitment & screening to monitoring participants throughout complex clinical studies
Dr Emma Law weighs the promise of AI voice agents against the human touch of clinicians in dementia trials using the Cognitive Dementia Rating Scale.
Dr Emma Law explores challenges & best practices in recruiting participants for clinical trials, highlighting strategies to improve success in dementia research
Some people say no to taking part in research. Dr Emma Law explores why, and shares ways we can respond with respect and understanding.
Dr Emma Law explores the hallmarks of a strong clinical research team—clear roles, open communication, shared responsibility, and a sense of humour.
Dr Emma Law reflects on key lessons from her first clinical trial, highlighting challenges, organisation, and best practices. Read more.
Dr Emma Law, a clinical trials expert with over 35 years of experience, shares insights into the complexities and realities faced by clinical trial raters.